SIMBOSPROST: Prevalence of metabolic syndrome and osteoporosis in prostate cancer patients treated with radiotherapy and androgen deprivation therapy: A multicentre, cross-sectional study by Samper Ots, Pilar M et al.
reports of practical oncology and radiotherapy 2 0 ( 2 0 1 5 ) 370–376
Available  online  at  www.sciencedirect.com
ScienceDirect
jo ur nal home p ag e: ht tp : / /www.e lsev ier .com/ locate / rpor
Original research article
SIMBOSPROST:  Prevalence  of metabolic  syndrome
and osteoporosis  in  prostate  cancer  patients
treated with  radiotherapy  and  androgen
deprivation therapy:  A multicentre,  cross-sectional
study
Pilar Ma Samper Otsa,∗, Julia Luisa Muñoz Garcíab, Yesika Ríos Kavadoyb,
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Aim: To assess the prevalence of metabolic syndrome (MetS) and osteoporosis in patients
with prostate cancer (PCa) treated with radical radiotherapy (RT) with or without androgen
deprivation therapy (ADT).
Background: Worldwide, the prevalence of MetS is estimated to range from 20% to 25% of
the  adult population. However, prevalence rates are much higher in PCa patients (pts) who
undergo ADT.
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Materials and methods: Multicentre cross-sectional study of 270 pts in Spain with PCa. Patients
were divided into 3 groups based on the duration of ADT (6, 12–18, ≥24 months) and com-
pared to a control group without ADT. MetS was defined according to NCEP ATP III criteria.
Osteoporosis was assessed by DEXA.
Results: A total of 270 pts, treated from November 2011 to October 2012, were included.
Of  these, 122 pts (47%) fulfilled the criteria for MetS. The median age of this group was
significantly higher (71.3 vs. 69.38 years, p = 0.028). MetS prevalence was 50% in the control
group. In pts who received ADT, prevalence was 44.8% after 6 months of ADT, 45.3% after
12–18 months, and 50% after ≥24 months (pns). Most pts (168/270; 62%) underwent DEXA.
Of  those tested, 78 (46.4%) had osteopenia and only 11 (6.5%) had osteoporosis.
Conclusions: The prevalence of MetS in pts with PCa treated with radical RT was higher
(47%) than in the general population. However, there were no significant differences in the
duration of ADT administration. The prevalence of osteoporosis was low. These findings
suggest that the prevalence of MetS in PCa patients may be higher than previously reported.
©  2015 Greater Poland Cancer Centre. Published by Elsevier Sp. z o.o. All rights reserved.
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levels of glucose, total and HDL-cholesterol, triglycerides and
testosterone were assessed and monitored.
The presence of MetS was defined according to the updated
NCEP ATP III4 by the presence of 3 or more  of the following.  Background
ost patients diagnosed with prostate cancer (PCa) will be
reated with surgery and/or radical radiotherapy. In many
ases, these patients will also receive androgen deprivation
herapy (ADT), which, when combined with radical radiother-
py, has been shown to modestly improve survival in locally
dvanced and high-risk disease.1,2 However, despite its ben-
ficial effects on survival, ADT may also induce numerous
dverse effects, including sexual and cognitive dysfunc-
ion, bone mass loss, insulin resistance, dyslipidemia, and
naemia.3
Several of these adverse effects overlap with the metabolic
yndrome (MetS), a combination of interrelated risk factors
hyperglycemia, hypertension, hypertriglyceridemia, low lev-
ls of high-density lipoproteins (HDL) cholesterol, and central
besity) for the development of cardiovascular disease (CVD)
nd type 2 diabetes. While the worldwide prevalence of MetS
n the general population is estimated to range from 20% to
0%,4 MetS prevalence is reported to be approximately 50%
n PCa patients treated with ADT.5 Rates of osteoporosis are
lso higher in this patient population (35.4–49.2%) versus the
eneral population.6,7
In most cases of PCa, the disease progresses relatively
lowly, even without treatment. As a consequence, a large
ercentage of these patients will ultimately die of causes unre-
ated to the cancer itself. In some cases, however, the cause
f death has been attributed to the treatment itself,8 par-
icularly ADT, which has been linked to the development of
etS and diabetes.6,9 Nevertheless, the question of whether
DT induces the development of MetS remains uncertain. A
ecent report10 found that although ADT appears to induce
hanges in some of the components of MetS after 12 months
f administration, it does not appear to increase rates of
ull MetS. However, other studies have reported that preva-
ence may increase as a function of the duration of ADT
dministration.11–13 As a result, the long-term association
etween MetS, osteoporosis, and ADT remains controversial
nd poorly understood, as a recently reported meta-analysis
ound.52.  Aim
Given the knowledge gap described above, the present study
was carried out in a large cohort of PCa patients to determine
the prevalence of MetS and osteoporosis after short-term (<6
months), medium-term (12–18 months), and long-term (≥24
months) administration of ADT. The main aim was to deter-
mine whether the prevalence of these conditions increases
with duration of ADT administration. The data presented here
provide an update to our interim analysis, reported in the year
2013.14
3.  Materials  and  methods
This was a multicenter cross-sectional study of 270 patients
diagnosed with localized intermediate or high risk PCa accord-
ing to NCCN criteria. All patients were treated with radical RT
without ADT (50 pts) or with ADT (220 pts). Patient character-
istics at diagnosis are shown in Table 1.
The inclusion criteria were as follows: (1) histologically
confirmed PCa, (2) localized intermediate or high-risk PCa
according to NCCN criteria, (3) scheduled for treatment with
radical RT. Patients with nodal involvement, metastasis, or
previous prostatectomy with adjuvant RT were excluded. The
270 patients who met  the inclusion criteria during the study
period (November 2011 to October 2012) were included.
The patient cohort was divided into four groups according
to the duration of ADT administration, as follows: group 1, no
ADT (50 pts); group 2, 6 months of ADT (60 pts); group 3, 12–18
months of ADT (99 pts); and group 4, ≥24 months ADT (61 pts).
All patients were interviewed to obtain detailed informa-
tion regarding family and personal history of hypertension,
hyperglycemia, hypercholesterolemia, hypertriglyceridemia
and specific treatment for those conditions. Waist circumfer-
ence, blood pressure, weight, and height were measured and
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Table 1 – Characteristic of prostate cancer and treatment.
No ADT ADT
N 270 50 220
Median age (range) 71 years (51–89) 68 years 71 years
Median PSA (range) 10.5 ng/ml (2.53–268.20) 13.38 ng/ml 24.9 ng/ml
Tumour stage
• T1c-T2a 85 (31.5%) 24 (8.8%) 61 (22.5%)
• T2b-T2c 136 (50.3%) 20 (7.4%) 116 (42.9%)
• T3a 31  (11.5%) 6 (2.2%) 25 (9.25%)
• T3b 18 (6.6%) 0 18 (6.6%)
Gleason
• ≤6 69 (25.6%) 12 (4.4%) 57 (21.1%)
• 7 94 (34.8%) 28 (10.3%) 66 (24.4%)
• ≥8 105 (38.9%) 8 (2.9%) 97 (35.9%)
• Unknown 2 (0.7%) 2 (0.7%) 0
Risk group
• Intermediate 100 (33.3%) 31 (11.4%) 59 (21.8%)
nificantly correlated with MetS included a family history of
diabetes (57.6% vs. 44%, p = 0.045), and a personal history of
obesity (70% vs. 45.5%, p = 0.039), hypertension (59% vs. 21.9%,• High 161 (59.6%) 
• Very high 19 (7%) 
Median dose EBRT 78 Gy (66.6–80.0)
five risk factors: (1) waist circumference ≥102 cm,  (2) fasting
glucose ≥110 mg/dL or previously diagnosed type 2 diabetes,
(3) serum triglyceride level ≥150 mg/dL or pharmacological
treatment for it, (4) systolic blood pressure ≥130 mm Hg or
diastolic blood pressure ≥85 mm Hg or previously diagnosed
hypertension, and (5) high-density lipoprotein (cHDL) choles-
terol <40 mg/dL.
Osteoporosis was diagnosed by dual energy X-ray absorp-
tiometry (DEXA) and considered to be present when the T
score at the hip or spine was ≤2.5. Sixty-two percent (168/270)
pts underwent DEXA testing, as follows: 22/50 pts in group 1,
27/60 pts in group 2, 70/99 in group 3, and 49/61 pts in group 4.
The study was approved by all the Clinical Research Ethics
Committees at each of the participating hospitals. All patients
were required to sign an informed consent form to participate.
4.  Results
4.1.  Metabolic  health
Height (cm), weight (kg), waist circumference (cm), sys-
tolic and diastolic blood pressure (mm  Hg), glycemia (mg/dL),
total cholesterol (mg/dL), HDL-cholesterol (mg/dL), triglyceride
(mg/dL), testosterone in ng/ml, and body mass index (BMI) are
shown in Table 2.
As Table 2 shows, the only significant differences between
the four groups were as follows: diastolic blood pressure
(p = 0.004) and testosterone levels (p = 0.000) (both of which
were higher in the control group), and BMI, which was higher
in group 4 (patients with ≥24 m ADT) (p = 0.029).
The majority of pts (232 out of 270; 86%) were overweight.
By group, the percentage of overweight pts was as follows:
group 1 (78%), group 2 (80%), group 3 (88%), and group 4 (95%)
(Fig. 1). Obesity correlated with lower levels of HDL cholesterol
(p = 0.020) and testosterone levels (p = 0.007).4.2.  Metabolic  syndrome
The number and percentage of patients who fulfilled the
criteria for each of the five NCEP components of MetS19 (7%) 142 (52.5%)
0 19 (7%)
were as follows: waist circumference ≥102 cm (158/267
pts; 59.2%); HDL-cholesterol ≤40 mg/dL (25/259 pts; 10%);
triglyceride levels ≥150 mg/dL or receiving pharmacological
treatment for hypertriglyceridemia (86/261pts; 33%); blood
pressure > 130/85 mm Hg or receiving pharmacological treat-
ment for hypertension (221/270 pts; 81.9%); and fasting glucose
≥110 mg/dL, previously diagnosed type 2 diabetes, or phar-
macological treatment for diabetes (100/270 pts; 37%). No
statistically significant differences in any of these parameters
were observed between the four groups (data not shown).
MetS was assessed in 259 out of 270 patients (11 pts were
not evaluable for MetS due to missing data), as follows: 46/50
pts in group 1; 58/60 in group 2; 97/99 in group 3; and 58/61
in group 4. Based on the NCEP ATP III criteria, 122 pts (47%)
fulfilled the diagnostic criteria for MetS.
Patients with MetS were significantly older (median age,
71.3 vs. 69.38 years, p = 0.028). Risk factors found to be sig-Fig. 1 – Body mass index by study group.
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p = 0.000), or diabetes (76.4% vs. 39.2%, p = 0.000). The metabolic
profile of pts according to the presence or not of MetS is shown
in Table 3. The patients with MetS showed a non-significant
trend towards lower testosterone levels.
4.3.  Analysis  by  study  group  (Table  4)
The groups did not differ significantly in terms of MetS preva-
lence: 50% in group 1, 44.8% in group 2, 45.3% in group 3, and
50% in group 4. The only pts with normal testosterone levels
were those in group 1 (no ADT) who did not develop MetS.
A diagnosis of MetS was significantly correlated with the
following factors: personal history of hypertension and anti-
hypertensive treatment (groups 1, 2, 3); family history of
diabetes (group 2); and personal history of diabetes and antidi-
abetic treatment (groups 3 and 4)
4.4.  MetS  in  high-risk  prostate  cancer
The presence of MetS did not correlate with any of the fol-
lowing parameters: NCCN risk group (p = 0.892), Gleason score
(p = 0.820), or tumour stage (p = 0.934).
4.5.  Bone  health
Of the 168 pts who underwent DEXA testing, 78 (46.4%) pre-
sented osteopenia. By study group, osteopenia rates were as
follows: group 1, 11/22 pts (50%); group 2, 13/27 pts (48.1%);
group 3, 29/70 pts (41.4%); and group 4, 25/49 (51%). These
differences were not significant. Osteoporosis was present in
only 11 patients (6.5%), by group (1, 2, 3, 4, respectively) as fol-
low: 2 pts (9.1%); 1 pt (3.7%); 6 pts (8.6%); and 2 pts (4.1%). No
fractures were observed. None of these small differences were
significant.
Neither osteopenia nor osteoporosis were significantly
correlated with age. Patients with normal bone mineral den-
sity (BMD) had testosterone levels of 0.66 ± 1.46 ng/ml while
patients with osteopenia had marginally (non-significant)
higher levels (0.71 ± 1.48 ng/ml). In contrast, patients with
osteoporosis presented significantly higher levels of testos-
terone (2.16 ± 4.44 ng/ml; p = 0.036).
4.6.  Discussion
In this study, our primary aim was to assess the prevalence
rates of MetS and osteoporosis in patients treated with RT and
ADT. As our results show, there were no significant differences
in the prevalence rates for either MetS or osteoporosis, regard-
less of the duration of ADT. Moreover, we found no significant
differences in the prevalence of these conditions, regardless
of whether ADT was administered or not. These findings sug-
gest that ADT does not increase rates of MetS or osteoporosis,
even after long-term administration.
In men, low testosterone levels are associated with
increased insulin resistance, type 2 diabetes and MetS.
Since ADT reduces testosterone levels, pts with PCa who
receive ADT are, at least theoretically, at a higher risk of
developing MetS. Androgen suppression also induces other
metabolic alterations, particularly insulin resistance,15,16 and
several studies have shown that ADT increases abdominal fat
374  reports of practical oncology and radiotherapy 2 0 ( 2 0 1 5 ) 370–376
Table 3 – Metabolic profile according to the presence or not of MetS.
Evaluable patients: n = 259 MetS No MetS p
N 122 (47%) 137 (52.8%)
Waist circumference (cm) 110.21 100.36 0.000
Systolic blood pressure (mm Hg) 145.52 136.80 0.000
Diastolic blood pressure (mm Hg) 78.50 74.94 0.010
Glycemia (mg/dL) 122.83 103.08 0.000
Triglyceride (mg/dL) 167.38 102.91 0.000
HDL-cholesterol HDL (mg/dL) 50.89
Total cholesterol total (mg/dL) 201.43 
Testosterone (ng/ml) 0.58 
and triglycerides while lowering insulin sensitivity,3,17 thus
increasing the probability of developing MetS.
The aetiology of MetS is not yet fully understood.18 How-
ever, there are many  interrelated factors that are thought to be
important in the development of this syndrome. Most patients
are old, obese, sedentary and have a certain degree of insulin
resistance. Central abdominal obesity is a physical manifes-
tation of this metabolic state. Insulin resistance in fat cells
results in the hydrolysis of stored triglycerides, which raises
the free fatty acids in the blood plasma. These free fatty acids
are absorbed by the liver, leading to an increase in very low
density lipoproteins (VLDL), a decrease in HDL, and a non-
alcoholic fatty liver. Insulin resistance in the muscles and a
reduction in its intake in the liver reduce the storage of glu-
cose, which will raise the level of glucose.
To our knowledge, only three previous cross-sectional stud-
ies have assessed MetS prevalence in PCa patients undergoing
ADT.11,12,13 In one of those studies, Braga-Basaria et al.12
reported a MetS prevalence of 20% in the control group vs.
22% in PCa patients without ADT and 55% in patients who
underwent ADT. A more  recent study by Cleffi et al.13 com-
pared two groups of PCa pts: in one group, pts received a mean
of 15 months of ADT while the other group did not undergo
ADT, reporting a significant difference in MetS prevalence
(54% vs. 24%, respectively). The most recently published cross-
sectional study was conducted by Morote et al.11 who found a
MetS prevalence of 32% in a control group (no PCa) vs. 36% in
PCa patients without ADT treatment, and 51% in patients who
received ADT. Relevant to our study, those authors observed
that MetS prevalence increased progressively over time in the
ADT group (44% vs. 57%, respectively, with <3 vs. >3 years of
ADT). In contrast, we  found no significant increase in rates of
MetS over time. The reasons for these differences are not clear
and more  research is needed to clarify this.
Morote and colleagues11 observed that the percentage
of patients with waist circumference ≥102 cm and glucose
≥110 mg/dL was significantly higher in patients who had
undergone ADT vs. the control group, while no significant
differences were observed in the remaining components of
MetS. In our study, we  also assessed these factors individually;
however, in contrast to those authors, we did not find any sig-
nificant differences between the study groups. However, we
did observe that in patients who received >12 months of ADT
(groups 3 and 4), the development of MetS was significantly
correlated with a personal history of diabetes or treatment
thereof.
ADT increases fat mass and may, therefore, lead to obe-
sity. Not surprisingly, the vast majority of pts in our study61.24  0.000
205.51 0.397
0.89 0.407
(86%) were overweight. Interestingly, in group 1, while just over
three-quarters (78%) of patients were overweight, the corre-
sponding figure was 95% in group 4, the group with the longest
duration of ADT treatment. In fact, the prevalence of over-
weight in group 4 was significantly higher than in the other
groups, suggesting that long-term use of ADT may play a role
in promoting obesity. In addition, long-term use of ADT was
associated with significantly lower HDL cholesterol and testos-
terone levels. Basaria et al.16 found that patients on long-term
ADT are at risk of developing insulin resistance and hyper-
glycemia. Our results seem to confirm that finding, as we
found that hyperglycemia is more  common among patients
who receive long-term ADT (groups 3 and 4) and who  fulfil the
criteria for MetS.
One of the main differences between our findings and those
reported by other authors is the relatively high percentage
(50%) of pts in the control group with MetS. Even though these
patients did not receive ADT, the percentage who  met  the cri-
teria for a diagnosis of MetS was nearly double that of the
general population. This finding may be partially age-related:
the median age of these patients was 71 and testosterone
levels are known to decrease with age. Indeed, in the non-
ADT treatment group, we found that the patients with MetS
had significantly lower levels of testosterone (2.7 vs. 5.1 ng/ml)
than men  without MetS. Another explanation may be related
to the potential contribution of MetS to the subsequent devel-
opment of PCa.19 Conteduca et al.19 reported that testosterone
levels are inversely related to total cholesterol, LDL cholesterol,
and triglycerides, and positively related to serum HDL  choles-
terol. This finding suggests that MetS may be an important
aetiological factor in the development of prostate cancer, and
may help explain why patients with PCa tend to have a higher
prevalence of MetS, even without ADT.20,21 Certainly, the data
from our study, in which 50% of men  without ADT fulfilled the
criteria for MetS, appear to support this hypothesis, and sev-
eral studies have correlated metabolic alterations with more
advanced disease and with high-grade prostate cancer.22,23
After definitive therapy for localized prostate, men  with MetS
might have a higher risk of developing PSA recurrence and
metastases. The presence of obesity and other components of
MetS have also been associated with an increased risk of PCa
mortality.6,9
4.7.  Osteoporosis  and  osteopeniaADT is reported to cause a 3–5% annual decrease in BMD;
as a result, PCa patients treated with ADT have a signifi-
cantly lower BMD than non-treated patients.24 The prevalence
reports of practical oncology and radio
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of osteopenia and osteoporosis is known to increase with
age, which in part explains the higher rates of these condi-
tions in PCa patients, who tend to be older than the general
population.25 Baseline studies in patients with newly  diag-
nosed PCa have shown a high prevalence (ranging from 60%
to 80%) of osteopenia and osteoporosis, even without hor-
monal treatment.26 One study27 reported a 35% prevalence
in hormone-naive patients; however, in pts undergoing ADT,
the prevalence increased steadily, reaching 43% after 2 years,
60% after 6 years, and 81% after 10 or more  years. In our
study, 46.4% had osteopenia, while osteoporosis was present
in only 11 patients (6.5%). This result was somewhat sur-
prising, especially in the light of the aforementioned rates
of osteoporosis.28 While we  are not sure of the explanation
for this discrepancy, we hypothesize that lifestyle modifica-
tion advice given by treating physicians (e.g., advice to lift
weights, and to limit smoking, alcohol, and caffeine consump-
tion, and the use of calcium and vitamin D supplementation)
may have been implemented to prevent the development
of osteoporosis. This seems especially likely given that the
risks of developing osteoporosis and bone fractures are well-
known.
4.8.  Study  limitations
The main limitation of this study is its cross-sectional design,
which does not permit us to evaluate changes in patient char-
acteristics over time. Another limitation is that we  do not have
data on any interventions that may have been implemented
by treating physicians to mitigate any treatment-related
alterations in the study variables, such as anti-hypertensive
treatments. As a result, this could have impacted the study
results. However, we believe that the large sample size and the
presence of a control group may have minimized any biases
of this nature.
5.  Conclusions
This cross-sectional study confirms previous reports that the
prevalence of MetS in patients with prostate cancer is signif-
icantly higher than in the general population. In contrast to
previous reports, we did not find any increase in MetS preva-
lence even after medium-to-long term use of ADT. However, in
this study, the prevalence of diabetes was higher in patients
who underwent more  than 12 months ADT and overweight
was significantly greater in patients who received more  than 2
years of androgen deprivation. The prevalence of osteoporosis
was low in all the study groups. Taken together, these findings
suggest that ADT does not appear to increase the rates of MetS.
Nevertheless, given the contrasting findings from other stud-
ies, longer term prospective trials would help to clarify this
issue.
Our data confirm previous reports of the association
between ADT (particularly long-term administration) and
metabolic alterations. For this reason, patients treated with
ADT should be carefully monitored during treatment and
steps should be taken to address any metabolic disturbances
or changes in bone mineral density that arise.
d rad
r
1
1
1
1
1
1
1
1
1
1
2
2
2
2
2
2
2
2
28. Lassemillante A-CM, Doi SAR, Hooper JD, Prins JB, Wright376  reports of practical oncology an
Conflict  of  interest
None declared.
Financial  disclosure
None declared.
Acknowledgements
We  wish to thank Bradley Londres for carefully editing this
manuscript. We  also would like to express our thanks to Astel-
las Pharma S.A. for their support.
 e  f  e  r  e  n  c  e  s
1. Sridharan S, Warde P. The management of high-risk, locally
advanced, prostate cancer radiation therapy. Can Urol Assoc J
2012;6(October (5)):393–5.
2. Bastian PJ, Boorjian SA, Bossi A, et al. High-risk prostate
cancer: from definition to contemporary management. Eur
Urol 2012;61(June (6)):1096–106.
3. Levy ME, Perera S, van Londen GJ, Nelson JB, Clay CA,
Greenspan SL. Physical function changes in prostate cancer
patients on androgen deprivation therapy: a 2-year
prospective study. Urology 2008;71(April (4)):735–9.
4. Grundy SM,  Brewer HB, Cleeman JI, Smith SC, Lenfant C.
Definition of Metabolic Syndrome Report of the National
Heart, Lung, and Blood Institute/American Heart Association
Conference on scientific issues related to definition.
Circulation 2004;109(January (3)):433–8.
5. Bosco C, Crawley D, Adolfsson J, Rudman S, Van Hemelrijck
M.  Quantifying the evidence for the risk of metabolic
syndrome and its components following androgen
deprivation therapy for prostate cancer: a meta-analysis.
PLOS ONE 2015;10(3):e0117344.
6. Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome.
Lancet 2005;365(9468):1415–28.
7. Saylor PJ, Morton RA, Hancock ML, Barnette KG, Steiner MS,
Smith MR. Factors associated with vertebral fractures in men
treated with androgen deprivation therapy for prostate
cancer. J Urol 2011;186(2):482–6.
8. Riihimäki M, Thomsen H, Brandt A, Sundquist J, Hemminki
K. What do prostate cancer patients die of? Oncologist
2011;16(February (2)):175–81.
9. Galassi A, Reynolds K, He J. Metabolic syndrome and risk of
cardiovascular disease: a meta-analysis. Am J Med
2006;119(October (10)):812–9.
0. Morote J, Gómez-Caamaño A, Alvarez-Ossorio JL, et al. The
metabolic syndrome and its components in patients with
prostate cancer on androgen deprivation therapy. J Urol
2015;193(6):1963–9.
1. Morote J, Ropero J, Planas J, et al. Metabolic syndrome in
patients with prostate cancer undergoing androgen
suppression. Actas Urol Esp 2014;38(June (5)):285–9.2. Braga-Basaria M, Dobs AS, Muller DC, et al. Metabolic
syndrome in men  with prostate cancer undergoing long-term
androgen-deprivation therapy. J Clin Oncol 2006;24(August
(24)):3979–83.iotherapy 2 0 ( 2 0 1 5 ) 370–376
3. Cleffi S, Neto AS, Reis LO, et al. Androgen deprivation therapy
and morbid obesity: do they share cardiovascular risk
through metabolic syndrome? Actas Urol Esp 2011;35(May
(5)):259–65.
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